Pimavanserin and Parkinson’s Disease Psychosis: A Narrative Review
Pimavanserin and Parkinson’s Disease Psychosis: A Narrative Review
About this item
Full title
Author / Creator
Publisher
Basel: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Basel: MDPI AG
Subjects
More information
Scope and Contents
Contents
Pimavanserin (PMV) is the first approved drug for treating hallucinations and delusions in Parkinson’s disease (PD) psychosis. Psychosis is one of the leading causes of nursing home placement in people with PD. Furthermore, hallucinations are a more frequent cause of institutionalization than motor disability or dementia related to PD. The manageme...
Alternative Titles
Full title
Pimavanserin and Parkinson’s Disease Psychosis: A Narrative Review
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_65cbd02a7e374c0a8d67ad0cce650526
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_65cbd02a7e374c0a8d67ad0cce650526
Other Identifiers
ISSN
2076-3425
E-ISSN
2076-3425
DOI
10.3390/brainsci12101286
